Developed over the past decade by MedPharm’s biologists and engineers, these models are designed to identify clinical risk early, enabling potential challenges to be addressed before they become costly failures in clinical trials.
MedPharm continuously evolves its biological models through internal innovation and close collaboration with clients, ensuring systems remain scientifically relevant as development needs and regulatory expectations advance.
MedPharm’s mucosal performance testing models use primary reconstructed tissues grown at an air–liquid interface.
Rather than relying on:
MedPharm uses epithelial cells isolated from healthy adult biopsies, expanded on Transwell inserts, and induced to differentiate into constructs that behave similarly to mucosal tissue in vivo.
MedPharm routinely evaluates nasal, bronchial, corneal, oral, rectal, and vaginal mucosal tissues.
Changes to any of these can dramatically affect where and how a formulation deposits in the nose. Traditional nasal cast models are typically one-size-fits-all and fail to capture key variables.
Using explant skin from healthy donors, MedPharm has identified dozens of clinically relevant inflammatory pathway targets and developed methods to activate those pathways.
These methods allow evaluation of both short-term and long-term pigmentation changes.
MedPharm developed a multi-TEWL meter to assess skin barrier integrity using transepidermal water loss. It integrates with MedPharm’s explant skin culture systems.
Although not yet used as full replacement assays, these in vitro irritation models are valuable tools for de-risking formulations prior to formal development studies.
